Allen Institute Launches $400M Brain Health Accelerator
The Allen Institute launched its Brain Health accelerator earlier this month, with $400 million in commitments over a 14-year initiative. The program’s initial disease targets are in neurodegeneration: Alzheimer’s, Parkinson’s, Huntington’s, ALS, and Lewy body dementia.
Leaders Forum at imec Captures Europe at an Inflection Point
In June, the campus of imec in Leuven, Belgium hosted the second annual Neurotech Leaders Forum at imec, bringing together executives, investors, researchers, and regulators from across Europe and the U.S. for two days of sessions spanning clinical translation, capital formation, regulatory strategy, and the emerging and converging frontiers of neurotechnology.
HGNS Vendors Plan Response to Plunging Stock Valuations
The neuromodulation market for treating obstructive sleep apnea is currently experiencing a transitional rough patch, though its long-term market potential remains robust. Nominally represented by Inspire Medical, Nyxoah, and LivaNova, the market has seen staggered timelines of adoption. Inspire has been commercializing its devices in the U.S. since 2014, whereas Nyxoah entered in 2025, and LivaNova is targeting a full market launch in the second half of 2027.
Lessons From the Strategics
One of the more memorable moments from the Medtech MVP conference was Medtronic CEO Geoff Martha’s advice that medtech firms must think beyond individual devices and toward broader ecosystems. That comment is especially relevant to neuromodulation, where therapies have historically been developed around discrete implantable or wearable devices. In pain, movement disorders, epilepsy, sleep, migraine, and other neurological conditions, the next generation of systems is increasingly likely to depend on patient selection tools, device-generated data, digital workflow support, remote monitoring, and payer-aligned outcome tracking.
Medtech Execs Discuss M&A Activity in Minneapolis
There has been a wealth of acquisitions in the neurotechnology and related medtech industries in recent months. Two of the largest acquirers have been Boston Scientific, which has picked up Axonics, Nalu, and Valencia Technologies, and Medtronic, which acquired SPR Therapeutics for over $600 million last month. Executives from both major strategics offered their insights on the M&A outlook at the recent Medtech MVP conference in Minneapolis.